AD/PD™ 2019, Lisbon - Speaker Lecture Titles

Speaker Lecture Titles


Last NameFirst Name CountryAbstract Title
Almeida
​Claudia
​Portugal
ENDOSOMAL TRAFFICKING DEFECTS IN AGING AND ALZHEIMER’S DISEASE
AsheKaren
USA

REPAIRING SYNAPTIC TRANSMISSION IN TAUOPATHIES BY TARGETING CASPASE-2

AttemsJohannes
UK
THE ROLE OF PYROGLUATMYLATED AMYLOID- Β IN THE PATHOGENESIS AND DIAGNOSIS OF ALZHEIMER'S DISEASE
Bezard
Erwan​France​

​PRIMATE-SPECIFIC SUSCEPTIBILITY TO NEURODEGENERATION AND SYNUCLEINOPATHY INDUCED BY PATIENT-DERIVED a-SYNUCLEIN EXTRACTS

BezprozvannyIlyaUSACALCIUM SIGNALING AND SYNAPTIC LOSS IN ALZHEIMER'S DISEASE
BlennowKaj SwedenTHE EXPANDED AD FLUID BIOMARKER TOOLBOX - PERFORMANCE FOR DIAGNOSTICS, THERAPY MONITORING AND SCREENING
BrooksDavidUKIMAGING THE TEMPORAL AND SPATIAL  INTER-RELATIONSHIPS OF PATHOLOGY WITH PET IN ESTABLISHED AND PRODROMAL ALZHEIMER'S AND PARKINSON'S DISEASE
BrundinPatrikUSANOVEL THERAPEUTIC TARGETS FOR PARKINSON'S DISEASE
BuGoujun USACENTRAL AND PERIPHERAL APOE IN COGNITION AND ALZHEIMER'S DISEASE
BueeLuc FranceIMPROVING TAU IMMUNOTHERAPY BY ENGINEERING NEW TOOLS: FROM IGGS TO VHHS
CheclerFrédéric FranceFUNCTIONAL PRESENILINS-PINK1 INTERPLAY
Chiba-FalekOrnitUSATHE TALE OF SNCA IN SYNUCLEINOPATHIES: AN INTERPLAY OF GENE DEREGULATION, AGING, AND THE NUCLEUS

Ciechanover

​Aaron
​Israel
​TBA
ClevelandDonUSAGENE SILENCING THERAPY IN AD AND PD
CudkowicsMeritUSAACCELERATING THERAPY DEVELOPMENT: LESSONS FROM NEURONEXT PHASE II NETWORK AND AMYOTROPHIC LATERAL SCLEROSIS
​Cuello
Claudio​​Canada

POTENTIAL TRANSLATIONAL VALUE OF EXPERIMENTAL THERAPEUTICS IN AD TRANSGENIC MODELS

​De Camilli
​Pietro
​USA

LIPID DYNAMICS IN THE ENDOCYTIC PATHWAY AND PARKINSON’S DISEASE GENES

De StrooperBart BelgiumTHE VARIOUS CELLULAR RESPONSES IN ALZHEIMER'S DISEASE
DiamondMarc USABIOCHEMISTRY AND STRUCTURAL BIOLOGY OF TAU PRIONS: IMPACT ON DIAGNOSIS AND THERAPY
FrenkelDan IsraelTARGETING PATHOLOGICAL PATHWAYS IN GLIA IN AD:  WHEN FRIENDS BECOME FOES
FrisoniGiovanni B.SwitzerlandTHE GUT MICROBIOTA IN AD: PRECLINICAL AND CLINICAL EVIDENCE OF AN ASSOCIATION
FutermanAnthonyIsraelLYSOSOMAL STORAGE DISEASES AND PD
GalvinJamesUSACAN DEMENTIA BE PREVENTED: LESSONS LEARNED AND APPLIED IN RESEARCH AND CLINICAL PRACTICE
Geula ChangizUSAELDERLY WITH SUPERIOR MEMORY AND THE FULL RANGE OF ALZHEIMER PATHOLOGY: RESILIENCE AND NEUROPROTECTION
GiladiNirIsrael
PERSONALIZED APPROACH TO TREATING PATIENTS WITH PARKINSON, THE ROLE OF GENETIC BACKGROUND
GoateAlisonUSABIOLOGICAL PATHWAYS IMPLICATED IN ALZHEIMER'S DISEASE RISK THROUGH GENETIC STUDIES
Gold
​Gabriel
​Switzerland
​TBA
GoldeTodd USAA PRECLINICAL  ROAD MAP TO DEVELOP COMBINATORIAL THERAPIES THAT CAN RESCUE BRIAN ORGAN FAILURE IN NEURODEGENERATIVE DISEASE
GrowdonJohnUSAMOLECULAR PET SCANS REVEAL THE BASIS OF DEMENTIA IN PARKINSON DISEASE
Haass
Christian​​Germany
​TREM2 – FROM BASIC MECHANISMS TO HUMAN PATIENTS
Hardy
​John
​UK
​GENOMICS AND NEURODEGENERATION 
Halliday
Glenda​​Australia
ROLE OF ALPHA-SYNUCLEIN AND LESSONS LEARNED FROM THE BRAIN

HenekaMichaelGermany

NLRP3 MEDIATED INNATE IMMUNITY IN ALZHEIMER'S DISEASE

HiguchiMakatoJapanIN-VIVO IMAGING OF TAU AND ALPHA-SYNUCLEIN PATHOLOGIES FROM MICROSCOPIC TO MACROSCOPIC SCALES
HoltzmanDavidUSAROLE OF APOE IN NEURODEGENERATION
HortJakubCzech  RepublicIMPACT OF AMYLOID PET ON DIAGNOSIS AND THERAPY IN CLINICAL SETTING
HymanBradleyUSA

 MOLECULAR MECHANISMS OF PROGRESSION IN ALZHEIMER DISEASE

InestrosaNibaldo C.ChileWNT SIGNALING HAS A KEY ROLE IN ALZHEIMER´S DISEASE: REGULATION OF APP PROCESSING AND TAU PHOSPHORYLATION
IsacsonOleUSALIPID AND PROTEIN INTERACTIONS CAUSING NEURODEGENERATIVE DISEASES
IwatsuboTakeshiJapanTOWARD DISEASE-MODIFYING THERAPY FOR ALZHEIMER'S DISEASE: JAPANESE ADNI AND A4 STUDIES
​Johnson
​Keith
​USA

​MOLECULAR PET BIOMARKERS OF ALZHEIMER PATHOLOGY: FOCUS ON PRECLINICAL DISEASE

Jeon

Beomseok

KoreaPERIPHERAL TISSUE BIOMARKER OF PARKINSON'S DISEASE
KooEdward USATBA
KorczynAmos D.IsraelTHE NEGLECTED AVENUES IN PREVENTING AD
Kulisevsky
​Jaime
​Spain

​HALLUCINATIONS IN PD: NEUROANATOMICAL CORRELATES

LaferlaFrankUSADEVELOPING THE NEXT GENERATION OF ALZHEIMERS ANIMAL MODELS.
LazarovOrly USAMOLECULAR MECHANISM OF NEURONAL VULNERABILITY IN ALZHEIMER'S DISEASE
Leahy
​Emer
​USA
​HIGH CONTENT PHENOTYPING AND MACHINE LEARNING APPROACHES TO AD DRUG DISCOVERY
LeeVirginiaUSA

TRANSMISSION OF MISFOLDED PROTEINS IN NEURODEGENERATIVE DISORDERS: A COMMON MECHANISM OF DISEASE PROGRESSION

LeeSeung-JaeKoreaMECHANISM OF ALPHA-SYNUCLEIN AGGREGATE PROPAGATION
LehericyStephaneFranceTBA
LemereCynthiaUSAFOCUSED ULTRASOUND IMPROVES THERAPEUTIC EFFICACY OF ANTI-PYROGLU3 ABETA IMMUNOTHERAPY IN APP/PS1 MICE
LiptonStuartUSA
SOLUBLE AGGREGATES OF α-SYNUCLEIN/ANTIBODY COMPLEXES ACTIVATE THE NLRP3 INFLAMMASOME IN HUMAN INDUCED PLURIPOTENT STEM CELL (hiPSC)-DERIVED MICROGLIA
MarekKenUSAHOW CAN BIOMARKERS IN PARKINSON DISEASE INFORM CLINICAL TRIALS – THE PPMI STUDY
MastersColinAustralia

A QUANTITATIVE APPROACH TO PRIMARY PREVENTION OF ALZHEIMER'S DISEASE: PROGRESS IN BLOOD-BASED SCREENS AND OTHER METHODS TO DETECT PERSONS AT RISK.

MichaelsonDaniel M. IsraelCOMPLIMENTARY APPROACHES TO ALZHEIMER  THERAPY  BASED ON REVERSAL OF THE HYPOLIPIDATION OF APOE4 AND  ON  ANTI-APOE4 IMMUNOTHERAPY
MirelmanAnat IsraelMOTOR –COGNITIVE INTERACTIONS IN NEURODEGENERATION
Mook-JungInheeKorea

THERAPEUTIC APPROACHES TO REDUCE PATHOLOGICAL TAU BURDEN IN THE BRAINS OF ALZHEIMER'S DISEASE MOUSE MODEL

MorganDaveUSAMARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE
Morizane AsukaJapanSTEM CELL THERAPY FOR PARKINSON'S DISESE PROGRESSING TO THE CLINIC
MorrisJohn MUSARACIAL SIMILARITIES AND DIFFERENCES IN ALZHEIMER BIOMARKERS
MuckeLennart USAPROTEINOPATHIES OF THE AGING BRAIN: FROM NETWORK DYSFUNCTION TO NEURODEGENERATION
MulthaupGerhardCanadaMOLECULAR DISSECTION OF AMYLOID CLEARANCE PATHWAYS: TOXIC VERSUS NON-TOXIC ABETA
NordbergAgneta SwedenTHE COMPLEXIITY OF TAU PET IMAGING IN EARLY DIAGNOSIS OF NEURODEGENERATIVE PROTEINOPATHIES
OuteiroTiagoGermanyTHE EFFECT OF ALPHA-SYNUCLEIN ON TRANSCRIPTION: INSIGHTS INTO SYNUCLEINOPATHIES
PetersenRonaldUSAPROGRESS TOWARD EVALUATING THE NIA-AA ALZHEIMER'S FRAMEWORK
PoeweWernerAustriaDISEASE-MODIFYING THERAPIES FOR PD: WHERE DO WE STAND ?
PolymenidouMagdalini SwitzerlandPATHOLOGICAL TDP-43 ASSEMBLIES AND DISEASE HETEROGENEITY
PradoMarcoCanadaCHOLINERGIC CONTROL OF PATHOLOGY AND COGNITION IN ALZHEIMER'S DISEASE
Ranum LauraUSAREPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION IN C9ORF72 ALS/FTD: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES
RascolOliverFranceNOVEL THERAPIES FOR PARKINSON DISEASE
RektorovaIrenaCzech RepublicCOMBINING IMAGING AND CLINICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LEWY BODY DISEASES
SchapiraAntonyUKNOVEL THERAPEUTIC STRATEGIES FOR DISEASE MODIFICATION IN PARKINSON DISEASE'
ScheltensPhilip The NetherlandsTAKING ALZHEIMER DIAGNOSIS TO THE NEXT LEVEL
SchlossmacherMichaelCanadaANTI-MICROBIAL EFFECTS OF SNCA AND LRRK2 INFORM CLINICAL TRIALS IN PARKINSON'S
SchmidtReinhold Austria

MRI-DETECTED IRON DEPOSITION IN NORMAL AGING AND DEMENTIA

SchmitzTaylorCanada
CORTICO-AMYGDALAR TOPOGRAPHIES OF ALZHEIMER’S DEGENERATION REFLECT THE CHOLINERGIC PROJECTION SYSTEM 

SchwartzMichal IsraelHARNESSING THE SYSTEMIC AND THE BRAIN'S SPECIFIC IMMUNE SYSTEM TO COMBAT ALZHEIMER'S DISEASE
SegalMenahemIsraelCALCIUM STORES AND ALZHEIMER'S DISEASE
SelkoeDennis J.USANEW CONCEPTS ABOUT THE BIOLOGY OF ALPHA-SYNUCLEIN IN VIVO
ShenJie USA

PRESENILIN AND APP IN FAMILIAL ALZHEIMER’S DISEASE

SnyderPeterUSANON-AMYLOID RETINAL BIOMARKERS FOR PRECLINICAL AD SCREENING
SoininenHilkkaFinlandEFFECTS OF FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE: NEW RESULTS FROM THE LIPIDIDIET TRIAL
SolomonBeka Israel

MOBILIZATION OF ENDOGENOUS MICROGLIA-LIKE HEMATOPOIETIC STEM CELLS AS A THERAPEUTIC STRATEGY FOR TREATMENT OF ALZHEIMER'S DISEASE

SoreqHermonaIsraelCIRCULAR RNAS CONTROL OXIDATIVE STRESS RESPONSES IN THE PARKINSON BRAIN
SperlingReisaUSATHE NEXT GENERATION OF ALZHEIMER'S DISEASE PREVENTION TRIALS  
SpillantiniMaria GraziaUK

CROSS-TALK BETWEEN NEURONS AND GLIAL CELLS IN NEURODEGENERATIVE DISEASES WITH TAU AGGREGATION

St. George-HyslopPeterCanadaMICROGLIAL SIGNALLING PATHWAYS INVOLVING TREM2, PLCG2, ABI3 AND CD33 IN MICROGLIAL DYSFUNCTION IN AD

​Stocchi

​Fabrizio 

​Italy

​TREATMENT OF OFF EPISODES IN PARKINSON' S DISEASE

SudhofTomUSATHE CELL BIOLOGY OF SYNAPSE FORMATION AND SYNAPSE DEGENERATION
TanziRudolph E.USAALZHEIMER'S DISEASE: AN AUTO-INNATE IMMUNE DISORDER?
TrojanowskiJohn Q. USA

TRANSMISSION OF SPECIFIC HUMAN TAUOPATHIES SUGGESTS DIFFERENT STRAINS OF PATHOLOGICAL TAU

TsaiLi-Huei USAGAMMA ENTRAINMENT USING SENSORY STIMULATION (GENUS) PROVIDES NEUROPROTECTION AND ENHANCES COGNITIVE FUNCTION 
Van BroeckhovenChristine Belgium

A PLETHORA OF GENETIC VARIATIONS IN CAUSAL AND RISK GENES ARE CONTRIBUTING TO EARLY-ONSET DEMENTIA

VassarRobertUSA
BACE1: THE BETA-SECRETASE ENZYME IN HEALTH AND ALZHEIMER'S DISEASE
WeinerMichaelUSAMEASURING BRAIN, CEREBROSPINAL FLUID, AND BLOOD FOR AMYLOID AND TAU TO DIAGNOSE ALZHEIMER'S DISEASE; LESSONS FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INTITIATIVE
WeinerHoward USAROLE OF MICROGLIA IN ALZHEIMER'S DISEASE 
WilcockDonnaUSATHERAPEUTIC TARGETING OF TREM2 FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WongPhilip USATARGETING TDP-43, A GUARDIAN OF THE TRANSCRIPTOME, FOR NEURODEGENERATIVE DISEASE
WszolekZbigniewUSAPERRY SYNDROME – PARKINSONIAN  CONDITION WITH TDP-43 PATHOLOGY
XuHuaxiUSATREM2 MEDIATES MICROGLIAL FUNCTION IN RESPONSE TO BETA-AMYOID
YueZhenyuUSAREGULATION OF a-SYNUCLEIN TRANSMISSION BY AUTOPHAGY IN CNS
ZetterbergHenrik SwedenDISEASE PROGRESSION IN ALZHEIMER'S AND PARKINSON'S DISEASES - WHAT HAPPENS TO THE FLUID BIOMARKERS?  
ZhouJiaweiChinaBALANCING THE INNATE IMMUNE SYSTEM IN THE BRAIN: INTERPLAY BETWEEN NG2 GLIAL AND MICROGLIAL CELLS
ZlokovicBerislavUSAALZHEIMER'S DISEASE: A MATTER OF BLOOD-BRAIN BARRIER DYSFUNCTION?